TEL AVIV, Israel , Nov. 21, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate update, in a Fireside Chat...

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Nov. 20, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2018 and provided a corporate update....

Additional Analyses Provide Insight into Treatment Effect of VB-111 TEL AVIV, Israel , Nov. 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), is reporting results today from its Phase 3 GLOBE study in patients with recurrent glioblastoma (rGBM) which was designed to evaluate VB-111 in...

TEL AVIV, Israel , Nov. 13, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

TEL AVIV, Israel , Oct. 23, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced the issuance by the European Patent Office (EPO) of Patent No. 2908865, a composition of matter patent which covers VB-111, VBL's lead drug candidate....

TEL AVIV, Israel , Oct. 11, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), announced today that a study entitled “MOSPD2: A Novel Therapeutic Target for the Treatment of CNS Inflammation,” is being presented today at the 34 th Congress of the European Committee for Treatment and...

<p>TEL AVIV, Israel , Sept. 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the company will provide a corporate overview at...

<p>These data, together with positive preclinical NASH data previously presented, support the potential of VBL’s lecinoxoid pipeline Recently granted US patent provides patent protection for lecinoxoids treatment of fibrosis until at least November 2035 and supports potential partnering opportunitie...

<p>Conference Call and Webcast at 8:30am Eastern Time Today VBL is well capitalized, cash sufficient for more than 3 years, beyond key inflection points VBL continues development of VB-111 for Ovarian Cancer with the OVAL Phase 3 trial ongoing, and intends to explore VB-111 activity in additional</p...

<p>TEL AVIV, Israel , Aug. 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webca...